David J. Roux, of Upperville, Virginia, is co-founder and senior director of private equity firm Silver Lake, where he previously served as Chairman and co-CEO. He was formerly Chairman and CEO of Liberate Technologies, Executive Vice President at Oracle Corporation and Senior Vice President at Lotus Development.
Mr. Roux began his technology career as co-founder and CEO of Datext, Inc., the first commercial CD-ROM publishing company. Previously, Mr. Roux was a board member of Intelsat, Business Objects S.A., Gartner, Inc., Serena Software, Symantec, Thomson, UGS Corp., and was the Chairman of the Board of Seagate Technology and Avaya. In addition to the JAX Board of Trustees, which he has chaired since 2015, he serves on the boards of the Institute for Health Metrics and Evaluation, National Audubon Society, and Bowdoin College.
A graduate of Harvard College, Mr. Roux holds an M.B.A. from Harvard Business School and an M. Phil. from King’s College, Cambridge University.
Thomas C. Barry is the President and Chief Executive Officer of Zephyr Management, L.P., an investment management company which he founded in 1994. Prior to founding Zephyr, Mr. Barry was President and CEO of Rockefeller & Co., the investment management arm of the Rockefeller family, from 1983 to 1993. Previously, he was employed by T. Rowe Price Associates, Inc. from 1969 to 1982, where among other responsibilities he was President of T. Rowe Price New Horizons Fund and Director of Research.
Mr. Barry holds an MBA from Harvard Business School and an undergraduate degree from Yale University, where he majored in Latin American Studies. He is a Chartered Financial Analyst.
Mr. Barry is currently a Director for the Massachusetts Mutual Life Insurance Company and is a member of the Council on Foreign Relations. He is a Trustee of the Hotchkiss School in Connecticut and the University School in Ohio. Mr. Barry also serves on the Yale University President’s Council on International Affairs and the Dean’s Council for Harvard University’s John F. Kennedy School of Government.
Mark S. Blumenkranz, M.D., is HJ Smead Professor and Chairman Emeritus in the Department of Ophthalmology at Stanford University. He is also cofounder and managing director of Lagunita Biosciences LLC, an early stage biotechnology and health sciences accelerator and medical investment company.
Dr. Blumenkranz received his Bachelor of Arts, Master of Medical Science and M.D. from Brown University, where he was in the medical school’s first graduating class. He completed his internship and residency in ophthalmology at Stanford and fellowship training in vitreo-retinal diseases at the Bascom Palmer Eye Institute. He returned to Stanford in 1992 and became the Chairman of the Department of Ophthalmology in 1997. He served in that capacity until 2015, during which time he spearheaded the creation of the Byers Eye Institute at Stanford and served as its founding Director.
An internationally known viretreo-retinal specialist, he is the recipient of multiple honors and awards in the field, including the American Academy of Ophthalmology Lifetime Achievement Award. He is a past President of the American University Professors of Ophthalmology (AUPO), and a past President of the Retina Society and the Macula Society. He serves as a member of the Steering Committee of the Audacious Goals Initiative of the National Eye Institute and is a Fellow of the Corporation of Brown University, where he is the Chair of the Medical School Committee.
Dr. Blumenkranz has a longstanding interest and expertise in technology innovation and transfer and he has served as a director of multiple private and public corporations. In addition to Lagunita Biosciences, he has co-founded and served as a director of Peak Surgical, Optimedica Corporation, Digisight Technologies and Oculeve Corporation, all venture-backed companies located in Silicon Valley. He also co-founded and served as Chairman of Adverum Biotechnologies and Digisight Technologies.
Otis Webb Brawley, M.D., MACP, FASCO, FACE, is a medical oncologist and epidemiologist. He serves as Bloomberg Distinguished Professor in the Department of Oncology of the School of Medicine and the Department of Epidemiology in the Bloomberg School of Public Health at Johns Hopkins University. He is a member of the National Cancer Institute Board of Scientific Advisors.
From 2007 to 2018, Dr. Brawley was Chief Medical and Scientific Officer of the American Cancer Society. In that role, he oversaw the largest private cancer research funding program in the U.S. He previously served as a professor in the Emory University School of Medicine and the Rollins School of Public Health and as a tenured senior investigator at the National Cancer Institute.
Among numerous awards, he received the Key to St. Bernard Parish for his work in the U.S. Public Health Service in the aftermath of Hurricane Katrina. He is a Master of the American College of Physicians, a Fellow of the American Society of Clinical Oncology, a Fellow of the American College of Epidemiology, and a member of the National Academy of Medicine. Dr. Brawley graduated from the University of Chicago, Pritzker School of Medicine.
Kathleen A. Corbet is founder and principal of Cross Ridge Capital, LLC, a venture capital and management consulting firm offering services in financial and operational best practices to early stage venture firms, state and local government agencies and municipalities and non-profit enterprises. Ms. Corbet has over 30 years in global leadership experience in the financial services industry. She served as President of Standard & Poor’s (S&P) from 2004-2007 and prior to that was with AllianceBernstein LP, where she served as Executive Vice President and CEO of the fixed income division.
A committed corporate, non-profit and civic leader, Ms. Corbet serves as a Lead Director and member of the board of directors of MassMutual Financial Group, as an Independent Director at TCP Capital and AxiomSL and as a Trustee for The Jackson Laboratory. She has served as a director/trustee for the Connecticut Housing Finance Authority, Pro Mujer International, and Boston College, her alma mater. Ms. Corbet has also served on the Board of Finance in New Canaan, CT and the Investment Advisory Committee of the New York Community Trust.
A graduate of Boston College and NYU’s Stern School of Business where she earned her MBA, Ms. Corbet is a frequent speaker and guest lecturer on women’s leadership and the financial services industry.
Lou D’Ambrosio is a seasoned chief executive across multiple industries. Most recently, he was Executive Chairman of Sensus, a clean technology company focused on conserving water and energy through smart sensors and communication systems. Mr. D’Ambrosio successfully led the sale of Sensus to Xylem. Prior to joining Sensus, Mr. D’Ambrosio served as CEO and Board member of Sears Holdings, comprised of Sears, Kmart, and Lands’ End. Previously, Lou served as CEO and board member of Avaya, Inc., a global telecommunications company. Earlier in his career, D’Ambrosio spent 16 years at IBM in domestic and international leadership roles in software and services and was appointed to its Worldwide Management Committee.
In addition to JAX’s Board of Trustees, Mr. D’Ambrosio serves or has served on numerous corporate and non-profit boards, including those of PSAV, Inc., UCT Coatings, Inc., and Walnut Street Theatre (Philadelphia).
Mr. D’Ambrosio holds an MBA from Harvard Business School and a B.S. in business from Penn State’s Schreyer Honors College.
Timothy Dattels is co-managing partner of TPG Capital Asia based in Hong Kong. He also is a member of the firm's executive committee. Prior to joining TPG in 2004, Dattels served as a partner and managing director at Goldman, Sachs & Co. from 1996 to 2000. During that time, he advised several of Asia's leading entrepreneurs and governments as head of investment banking for all Asian countries outside Japan. In addition, he served on the firm's management committee in Asia. He is also a member of Northstar Equity Partners' investment committee.
Dattels serves or has served on the Board of Directors of BlackBerry, Parkway Holdings, Primedia, Inc., Shangri-La Asia Ltd., and Sing Tao News Corporation. He is currently Vice Chair of the Board of Trustees of SFJazz. He received an M.B.A. from Harvard Business School and a bachelor of arts, with honors, from the University of Western Ontario.
Julie Hembrock Daum leads the North American Board Practice at executive search and leadership consulting firm Spencer Stuart, where she was a long-standing board member. She consults with corporate boards, working with companies of all sizes from the Fortune 10 to pre-IPO companies. She has conducted more than 1,000 board director assignments, recently recruiting outside directors for Johnson & Johnson, Whole Foods, Amazon, Saudi Aramco, Nike, numerous IPOs and spin-off boards.
A recognized expert on governance topics, Ms. Daum has been selected as one of the 50 Most Influential People in Governance by NACD/Directorship Magazine every year since its inception. Prior to joining Spencer Stuart, she was the executive director of the corporate board resource at Catalyst, where she managed all board of directors' activities and worked with companies to identify qualified women for their boards. Ms. Daum began her career as a consultant with McKinsey & Company in Los Angeles.
Ms. Daum is a graduate of the Wharton School at the University of Pennsylvania with an M.B.A. in corporate finance. She serves on the board of directors of Seacoast Bank and as a commissioner for the Women's Refugee Commission.
David D. Elliman is Chief Investment Officer of the Elmrock Group and is responsible for the asset portfolios of the constituent companies. He is a Founding Principal of the Elmrock Group of companies, which include Elmrock Capital Inc. and Stillrock Management, Inc., a registered investment advisor. He is also a founding partner of Elmrock Partners, which, along with affiliates, specializes in private equity, marketable equity, structured finance and asset securitization investments. Prior to Elmrock, he was a portfolio manager at Citibank.
Mr. Elliman serves or has served on the boards of a number of public and private companies. In addition to serving on the Board of The Jackson Laboratory, he has served as an Overseer of the College of Arts and Sciences of the University of Pennsylvania.
Mr. Elliman earned a B.A. in biology from the University of Pennsylvania, an M.S. in cell biology from the University of California at Irvine and an MBA in finance from the Wharton School, with honors.
Anthony B. Evnin, Ph.D. has been a Partner at Venrock, a venture capital firm, since 1975. He led Venrock’s entrance into and the first 25 years of its investments in biotechnology and the greater life sciences field.
Dr. Evnin currently serves on the Board of Directors of Juno Therapeutics, Cantel Medical, AVEO Pharmaceuticals, and Infinity Pharmaceuticals as well as two private companies. He was formerly a Director of over 40 companies, both public and private, in the life sciences area, including Centocor, Genetics Institute, IDEXX Laboratories, Dianon Systems, IDEC Pharmaceuticals, Athena Neurosciences, Sepracor, Triangle Pharmaceuticals, Caliper Life Sciences, Sugen, and Acceleron Pharma. He is a Member of the Boards of Overseers and Managers of Memorial Sloan Kettering Cancer Center, a Director of the New York Genome Center, a Member of the Board of Directors of the Albert and Mary Lasker Foundation, a Trustee Emeritus of Princeton University, and a Trustee Emeritus of The Rockefeller University.
Dr. Evnin received an A.B. in chemistry from Princeton University and a Ph.D. in chemistry from the Massachusetts Institute of Technology.
Steven B. Fink, J.D., serves as the Chief Executive Officer at Malibu Ventures. An investment professional, he has extensive experience building and managing technology companies. Mr. Fink has served on the boards of numerous publicly traded and privately held companies, including Nextera, Pillar Data Systems, Inc., Life Storage LLC, Leapfrog Enterprises Inc., and Nobel Learning Communities, Inc. He founded Knowledge Universe Inc. (now KinderCare Education) and serves as its founding partner and managing director.
Mr. Fink serves or has served on the Board of Trustees of Barnard College, Columbia University, the Herb Ritts Foundation Board, The Photographic Counsel of the Getty Museum, the American College of Physicians Foundation Board, the Board of the Smithsonian Institute Museum of American History, the UCLA Foundation Board, and the Board of Directors of City of Hope.
He holds a J.D., and an L.L.M. degree from the New York University and a B.S. from the University of California, Los Angeles.
Jeffrey Friedman, M.D., Ph.D., is the Marilyn M. Simpson Professor and head of the Laboratory of Molecular Genetics at Rockefeller University. He is a recipient of the 2010 Albert Lasker Basic Medical Research Award for his discovery of the hormone leptin and its role in regulating body weight. Dr. Friedman has received numerous other awards including the Gairdner Foundation International Award, the Passano Foundation Award, the Banting Lecture Award, and the Bristol-Myers Squibb Award for Distinguished Achievement in Metabolic Research. He is a member of the National Academy of Sciences.
Dr. Friedman graduated from Rensselaer Polytechnic Institute magna cum laude and received his medical degree from Albany Medical College of Union University. After completing two residencies at Albany Medical Center Hospital, Dr. Friedman began his career at Rockefeller as a postgraduate fellow and associate physician. He received a Ph.D. under the mentorship of Professor James Darnell, Jr., M.D., and was appointed assistant professor. Dr. Friedman was then promoted to associate professor and named head of the laboratory of molecular genetics at Rockefeller. He was then promoted to professor and subsequently appointed as the Marilyn M. Simpson Professor. Dr. Friedman also serves as the Chairman of Bay City Capital’s Scientific Advisory Board.
John A. Gibbons Jr., of Greenwich, Conn., is owner and managing partner of Odin Partners, an investment management firm based in New York City. He previously served as a Senior Vice President and Portfolio Manager at Lord, Abbett & Co. LLC.
Mr. Gibbons earned his M.B.A. from New York University and his B.A. from Bowdoin College, where he has served in numerous alumni volunteer leadership roles. He was elected a trustee emeritus of Bowdoin College in 2017 after serving as a trustee of the college for 15 years. He is also a trustee of the Gibbons Foundation.
Dr. Hewett serves as executive director of the Institute for Digital Engineering and Life Sciences--an organization working to create a new graduate school in Portland, Maine, that will focus narrowly on digital engineering and genomics/life sciences. Hewett recently retired as executive vice president and chief operating officer of The Jackson Laboratory (JAX). Since his arrival in 2004, he has overseen the launch of numerous research products and services; modernization of mouse production facilities; completion of new research laboratories in Bar Harbor, Maine; and the relocation and expansion of the Laboratory’s California operation. Dr. Hewett conceived and led the development of The Jackson Laboratory for Genomic Medicine and secured the State of Connecticut’s agreement to provide $291 million and 17 acres of land for its establishment. Dr. Hewett is a member of The Jackson Laboratory’s Board of Trustees and also served as a founding board member of the New York Genome Center, the founding chair of the Ellsworth Business Development Corporation and the Consulting Executive Director of the Institute of Digital Engineering and Life Sciences in Portland, Maine.
Prior to joining the Laboratory, as CEO of Atlantic Energy Partners and Neptune Regional Transmission System, Dr. Hewett successfully developed a $650 million underwater merchant D.C. electric transmission system connecting Long Island, N.Y., to New Jersey. At the same time, he also served as vice president and secretary to the Board of the Cianbro Companies. In the mid-1990s, Dr. Hewett served for three years as the chief operating officer of the Executive Branch of the state of Maine during Gov. Angus King's first term. He has held chief executive posts in the international pharmaceutical industry, in electric generation and in natural resource management, and has created companies and managed start-up projects in Asia, Europe and the United States. He is a Phi Beta Kappa graduate in political economy from Williams College and holds M.F.S., M.S. and Ph.D. degrees from Yale University, where he was a member of Sigma Xi.
Jean Hoffman is an independent board member and investor based in Portland, Maine. She has had a long and successful career in the pharmaceutical and healthcare industry. Most recently, she founded and built Putney into America’s leading generic drug company for pets, serving as the company’s president, CEO and chair of its Board from inception to its 2016 sale to Dechra Holdings US Inc., a subsidiary of Dechra Pharmaceuticals PLC.
Putney was Jean’s second successful exit for a company she founded and built. Previously, she founded Newport Strategies, Inc., and led that company as it built a global brand for its proprietary healthcare information technology systems until its 2004 acquisition by Thomson Reuters.
Jean began her career at the U.S.-China Business Council, where she advised U.S. companies on the establishment of business with China and Chinese entities on exporting to the U.S, leading to her subsequent career in the pharmaceutical industry. She then joined the Swiss-Asian Zuellig Group of Companies, eventually becoming CEO of ZetaPharm, a Zuellig subsidiary.
A graduate of Bowdoin College, where she majored in East Asian History and Government and Legal Studies, Jean has been honored with numerous awards, including a 2014 EY Entrepreneur Of The Year Award in the life sciences category for New England. She currently serves on the advisory board of the Cummings School of Veterinary Medicine at Tufts University and on the board of MedRhythms, Inc., based in Portland, Maine.
Rick Lannamann, President, Willowmere Investments, LLC, is a director of the Foreign Policy Association, a director of the Sarasota Orchestra and a past chair of the Orpheus Chamber Orchestra. In September 2014 he retired as Vice Chairman of Spencer Stuart to focus on private investing and board and philanthropic work. Prior to joining Spencer Stuart in 2002, Mr. Lannamann spent 23 years at Russell Reynolds Associates, another global search firm, where he founded the search industry’s first asset management practice, co-headed its global financial services practice, served on the executive committee and chaired the company’s investment committee. Earlier in his career, he was an investment analyst at US Trust, a vice president of the research division of Smith Barney, and senior vice president and portfolio manager at Management Asset Corporation.
A CFA charterholder, Mr. Lannamann served on the Board of Regents of the CFA Institute’s Financial Analysts Seminar and was a member of Institutional Investor’s U.S. Institute Advisory Council. He also chaired two CFA Institute conferences on managing investment organizations. He graduated from Yale College with a bachelor’s degree in economics in 1969 and earned an M.B.A. from Harvard Business School in 1973.
He now splits his time between homes in Osprey (Sarasota), Florida and Greenwich, CT.
Dr. Liu is the president and CEO of The Jackson Laboratory. Previously, he was the founding executive director of the Genome Institute of Singapore (2001-2011), and was the president of the Human Genome Organization (HUGO) from 2007-2013. Between 1997 and 2001, he was the scientific director of the National Cancer Institute's Division of Clinical Sciences in Bethesda, Md., where he was in charge of the intramural clinical translational science programs.
From 1987 to 1996, Dr. Liu was a faculty member at the University of North Carolina at Chapel Hill, where he was the director of the UNC Lineberger Comprehensive Cancer Center's Specialized Program of Research Excellence in Breast Cancer; the director of the Laboratory of Molecular Epidemiology at UNC's School of Public Health; chief of Medical Genetics; and the chair of the Correlative Science Committee of the national cooperative clinical trials group, CALGB. Dr. Liu is an international expert in cancer biology, genomics, human genetics, molecular epidemiology and translational medicine.
Dr. Liu's own scientific research has focused on the functional genomics of human cancers, particularly breast cancer, uncovering new oncogenes, and deciphering on a genomic scale the dynamics of gene regulation that modulate cancer biology. He has authored over 300 scientific papers and reviews, and co-authored two books. He obtained his B.S. in chemistry and psychology, as well as his M.D., at Stanford University. He served his internship and residency at Washington University's Barnes Hospital in St. Louis, followed by an oncology fellowship at Stanford. From 1982 to 1987 he was at the University of California, San Francisco, at the G.W. Hooper Foundation.
Neal Milch is Executive Chairman of the Board of Laundrylux, a North American supplier of commercial laundry equipment, laundry business solutions, and marketing services. He previously served as CEO of Laundrylux from 2007 until moving into the Executive Chairman role in 2018. Mr. Milch has also led several related businesses, including Pluslux LLC, a digital payments solution provider, which he founded. He served as the vice president of Global Marketing at Electrolux, based in Copenhagen, Denmark, before returning to Laundrylux in 2006. Mr. Milch is also a co-founder of Cbite, which focuses on thin film transistor (TFT) technology to enable organic light-emitting diode (OLED) display panels.
Mr. Milch holds a J.D. from Columbia University School of Law, with a focus on intellectual property; a B.A. from Stanford University; and also attended the London School of Economics.
George Montgomery was most recently a Partner at Gurnet Point Capital, a healthcare investment fund, where he headed the firm’s San Francisco office until 2019. Prior to joining Gurnet Point, George was a co-founder of Coherus Biosciences, a late stage biotechnology company focused on biosimilars. After helping start the company in early 2011, he served as the CFO, a member of the Executive Committee and a member of the Product Development Steering Committee. Prior to Coherus, George had over 25 years of experience in investment banking and worked across most sectors of the health care industry, including pharma/biotech, medical devices and services/health care information technology. George served as a Managing Director at Cowen and later JPMorgan H&Q. Prior to Cowen, he served as a Vice President at CSFB.
Mr. Montgomery received his B.A. in Political Science from Yale University and his MBA in Finance from the Wharton School at the University of Pennsylvania. He currently serves on the Board at REDF, a California-based non-profit, and the Yale Cancer Center Advisory Board. George also serves on the Board of the Yale Crew Association and is the current Treasurer.
Frank Moss, Director of Humatics, Inc., and AirLifting, Inc., is an entrepreneur and veteran of the software and computer industries who has spent his career building companies and bringing innovative technologies to market. His interest in using technology to address pressing social issues—such as human health—and to improve quality of life led him to co-found a cancer drug discovery company, Infinity Pharmaceuticals, and from there to the MIT Media Lab, where he served as director from 2006 – 2011 and where today he is Professor of the Practice and head of the New Media Medicine Group.
Dr. Moss began his career at IBM's scientific center in Haifa, Israel, where he also taught at the Technion, Israel Institute of Technology. He later held various research and management positions at IBM's Yorktown Heights (NY) Research Center, working on advanced development projects in the areas of networking and distributed computing. He went on to hold management positions at IBM, Apollo Computer, and Lotus Development Corporation, and was CEO and chairman of Tivoli Systems, which he took public in 1995 and merged with IBM a year later. He is a co-founder of many companies, including Stellar Computer, Bowstreet, Infinity Pharmaceuticals, and his latest start-up venture, Bluefin Labs. He is also an enthusiastic advisor to other young companies that share his vision of vastly better living through technology.
A former trustee of Princeton University, Dr. Moss is currently a member of the Advisory Council for Princeton’s School of Engineering and Applied Sciences. In addition, he chaired the advisory council for the creation of the Systems Biology Department at Harvard Medical School, where he remains an advisor. He earned his undergraduate degree, a bachelor of science in engineering, from Princeton and holds a Ph.D. in aeronautics and astronautics from MIT.
Dr. Dennis Paustenbach is President Emeritus of Cardno ChemRisk, a division of Cardno specializing in human and ecological risk assessment, as well as risk analysis of chemical and radionuclides in consumer products, contaminated sites, pharmaceuticals and medical devices. He is a board-certified toxicologist and industrial hygienist with nearly 30 years of experience in risk assessment, environmental engineering, ecotoxicology, and occupational health.
In 1985, Dr. Paustenbach founded ChemRisk as a joint venture with McLaren-Hart, a nationwide consulting firm, and later became President and Chief Executive Officer of McLaren-Hart Environmental. In 1997, he joined Exponent as Vice President responsible for leading the Health Sciences division. In 2003, he restarted ChemRisk as a separate enterprise that later merged with Cardno.
Dr. Paustenbach earned his Ph.D. in environmental toxicology from Purdue University, an M.S. in counseling psychology from Indiana State University, an M.S. in industrial hygiene and toxicology from the University of Michigan, and a bachelor of science in chemical engineering from Rose-Hulman Institute of Technology.
Jenny Rooke, Ph.D., is the founder and managing director of Genoa Ventures, a San Francisco-based life sciences venture firm. For over a decade, Dr. Rooke has been deploying capital at the frontiers of life sciences innovation, with a penchant for technology-fueled solutions and category-defying opportunities. She got her start in venture investing at Fidelity Biosciences, a Cambridge-based healthcare venture capital firm. Dr. Rooke then brought her combination of genetics domain expertise, strategic business acumen, and venture investing to the Gates Foundation, where she deployed and managed over $250M in funding in genetic engineering, diagnostics, and synthetic biology. She also played a key role in establishing the foundation’s investing function.
In 2014, Dr. Rooke launched 5 Prime Ventures, investing in life sciences innovation. She founded Genoa Ventures in 2018, building on the 5 Prime Ventures track record, in order to scale a proven, differentiated investing strategy focused on early-stage life sciences companies innovating at the intersection of biology, technology and data science.
Dr. Rooke earned her Ph.D. in Genetics from Yale University, where she was a National Science Foundation Fellow. She received her B.S. in Physics from Georgia Institute of Technology (Georgia Tech) in 1992.
Dr. Janet Rossant is President and Scientific Director of the Gairdner Foundation, Chief of Research Emeritus at Toronto’s Hospital for Sick Children (SickKids), and a world-renowned expert in developmental biology. As chair of The Jackson Laboratory’s Board of Scientific Counselors, she is an ex officio member of the JAX Board of Trustees.
Widely known for her studies of the genes that control embryonic development in the mouse, Rossant has pioneered techniques for following cell fate and altering genes in embryos. This work continues to resonate in medical genetic research. Her current research focuses on stem cell development and cell differentiation in the developing embryo, important areas for the study of birth defects as well as regenerative medicine.
Dr. Rossant trained at the Universities of Oxford and Cambridge, United Kingdom. She has been in Canada since 1977, first at Brock University and then at the Samuel Lunenfeld Research Institute within Mount Sinai Hospital in Toronto, from 1985 to 2005. She joined SickKids in 2005. Dr. Rossant has been recognized for her contributions to science with many awards, including the Ross G. Harrison Medal (lifetime achievement award) from the International Society of Developmental Biologists, the Killam Prize for Health Sciences, the March of Dimes Prize in Developmental Biology, the Conklin Medal from the Society for Developmental Biology, the CIHR Michael Smith Prize in Health Research, the 10th ISTT Prize from the International Society for Transgenic Technologies in Edinburgh, Scotland, and the 2018 L’Oreal For Women in Science Award. She is a Fellow of the Royal Societies of London and Canada, and is a foreign Associate of the U.S. National Academy of Science.
Geoffrey W. Smith is the founder and Managing Partner of Digitalis Ventures, a venture capital firm that invests in fundamental new ideas in math and science to address complex health problems. He is also a co-founder and General Partner of Ascent Biomedical Ventures, a New York City-based venture capital firm focused on early-stage life sciences investments.
A member of the Scientific Advisory Board for Brigham & Women’s Hospital in Boston, Geoff is a Visiting Scholar at Rockefeller University and an adjunct faculty member at the RU Center for Clinical and Translational Science. Previously, he was the founding Director of the Mount Sinai Institute of Technology and a Professor in the Department of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai.
Geoff received a B.A. (with honors) from Williams College and a J.D. from the University of Pennsylvania Law School.
Dr. Joan A. Steitz is Sterling Professor of Biophysics and Biochemistry at Yale University and a Howard Hughes Medical Institute Investigator. One of leading scientists in her field, Professor Steitz is best known for her pioneering work in RNA. She and her student Michael Lerner discovered and defined the function of small ribonucleoproteins (snRNPs) in pre-messenger RNA—the earliest product of DNA transcription—and she was the first to learn that these cellular complexes (snRNPs) play a key role in processing messenger RNA by excising noncoding regions and splicing together the resulting segments. Her breakthroughs into the previously mysterious splicing process have clarified the science behind the formation of proteins and other biological processes, including the intricate changes that occur as the immune system and brain develop.
Dr. Steitz earned her Ph.D. from Harvard University and her undergraduate degree from Antioch College. After completing postdoctoral work in Cambridge, England, she joined the Department of Molecular Biophysics and Biochemistry at Yale as an assistant professor and later became an associate and full professor, as well as chair of the department.
Dr. Steitz is the recipient of numerous honors and awards, including the Gairdner Foundation International Award, the Rosalind E. Franklin Award for Women in Science, and the National Medal of Science. She is a member of the Institute of Medicine and the National Academy of Science, a Fellow of the American Academy of Microbiology and a Fellow of the American Academy for the Advancement of Science.
As Chief Executive Officer and President of the Church Pension Group (CPG), Mary Kate Wold leads a $13 billion financial services enterprise that provides retirement, health, life insurance, property and casualty insurance, and other products and services to the Episcopal Church. She also serves as a member of the Board of Trustees of The Church Pension Fund, CPG’s governing body.
Mary Kate has served in a variety of leadership positions in the corporate, legal, and government sectors. Prior to joining CPG, she was a senior finance executive and principal corporate officer of Wyeth, one of the world’s largest pharmaceutical companies. Previously, she was a partner and chaired the tax practice group of Shearman & Sterling, a leading global law firm. Earlier in her career, she served in the Office of Tax Policy of the United States Department of the Treasury.
Mary Kate chairs the board of the Church Benefits Association, a national association of faith-based benefits organizations, and she serves on the vestry of Trinity Church Wall Street and on its investment committee. She is a former director and Chair of a publicly traded medical device company. Her professional affiliations include membership in the Women’s Forum of New York and Women Corporate Directors.
Mary Kate spent her childhood in Bottineau, North Dakota, a small rural community on the Canadian border. She graduated from Hamline University in St. Paul, Minnesota, summa cum laude with a B.A. in English and Theater, and was elected a member of Phi Beta Kappa. She later graduated cum laude from the University of Michigan Law School.